The Effect of a Novel Combined Hormonal Treatment Containing a GnRH-antagonist for Uterine Fibroids and Endometriosis on Hemostasis Parameters: a Prospective Cohort Study

Uterine fibroids and endometriosis are two frequent diseases among women of reproductive age. They can be responsible for chronic and/or menstrual pelvic pain and abnormal uterine bleeding. The first-line management of these conditions relies on medical treatment. Hormonal treatment with contraceptive pill can be effective, although up to 30% of patients do not respond to this line of treatment. In this context, GnRH antagonists have been introduced. By suppressing ovulation, they inhibit the action of the gonadal axis and thus can reduce bleeding and pain associated with uterine fibroids and endometriosis. More recently, the GnRH antagonist known as Relugolix has been associated with a low-dose oestradiol and progesteron-line molecule, a medication known as Ryeqo. The goal of this type of treatment is to suppress ovulation while also minimizing symptôms which may derive from lack of oestrogen and progesterone in reproductive age women.
While Ryeqo's efficacy has been proven by multiple large randomized controlled trials, its impact on blood coagulation has yet to be determined. Venous thromboembolism (VTE) is the main, potentially fatal, dleterious effect of oestrogen-containing hormonal treatmen, such as combined oral contraceptives (COC). Several epidemiological studies have found a 3-6 increase in the risk of VTE among women on COC. The thrombogenic risk can be assessed by measuring specific blood biomarkers, which are known to be correlated to the thrombogenic phenotype and allow an overview of the VTE risk prior to conducting large population-scale studies directly measuring the adverse event's prevalence.
The aim of this study is to document the effects of Ryeqo® on hemostasis parameters in order to estimate the risk of VTE associated with its employ. An improved understanding of the VTE risk associated with Ryeqo® will allow to adapt hormonal treatment based on each woman's personal risk profile.
The study will be explained to all women whose medical condition allows the prescription of Ryeqo. All women who give their consent to participate in the study will have a urinary pregnancy test and a blood sample drawn before beginning treatment with Ryeqo. A second visit will be scheduled at 3 months, throughout which a second blood sample will be drawn. A questionnaire including socio-demographic data and clinical symptoms will be completed both on the first and the second visit.

开始日期2025-09-30

申办/合作机构

Les Hôpitaux Universitaires de Genève

NCT06953076

/ RecruitingN/AIIT

MyomaS Aspect Transformation at Ultrasound During Relugolix Estradiol Noretisterone Treatment: MySaturn Study

Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery.
Ultrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.

开始日期2025-05-02

申办/合作机构-

NCT05739136

/ Active, not recruitingN/A

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care from healthcare providers (HCPs). The study is designed to evaluate the association between relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) exposure during pregnancy and subsequent fetal and infant outcomes.

开始日期2025-04-30

申办/合作机构

Sumitomo Pharma Co., Ltd.

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的临床结果

登录后查看更多信息

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的转化医学

登录后查看更多信息

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的专利（医药）

登录后查看更多信息

项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的文献（医药）

2025-09-01·FERTILITY AND STERILITY

Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2

Article

作者: Bouzegaou, Nadia ; Stewart, Elizabeth A ; Rakov, Viatcheslav G ; Venturella, Roberta ; Catherino, William H ; Vannuccini, Silvia ; Zaim, Souhil ; Munro, Malcolm G ; Perry, Julie S ; Wu, Rui ; Al-Hendy, Ayman

OBJECTIVE:

To assess the effects of relugolix combination therapy in women with uterine fibroids (UFs) and concomitant ultrasound-diagnosed adenomyosis.

DESIGN:

This post hoc analysis used pooled data from completers of the pivotal LIBERTY studies. The subgroup of women with adenomyosis and UFs was compared with the overall study population on selected efficacy and safety endpoints.

SUBJECTS:

Premenopausal women (aged 18-50 years) with diagnosed UFs (confirmed by ultrasonography) and heavy menstrual bleeding (assessed by the alkaline hematin method).

INTERVENTION:

Once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg of norethindrone acetate) or placebo for 24 weeks, or delayed relugolix combination therapy (40 mg of relugolix monotherapy for 12 weeks, followed by relugolix combination therapy for 12 weeks).

MAIN OUTCOME MEASURES:

Endpoints included the percentage of women with concomitant adenomyosis, the proportion of treatment responders (achieved or maintained a menstrual blood loss <80 mL and ≥50% reduction in menstrual blood loss volume from baseline over the last 35 days of treatment), the proportion of women achieving or maintaining amenorrhea over the last 35 days of treatment, and the change from baseline to week 24 in uterine volume and adverse events.

RESULTS:

A total of 111 women (18.2%) had a baseline diagnosis of concomitant adenomyosis (37 in the relugolix combination therapy group, 45 in the delayed relugolix combination therapy group, 29 in the placebo group) and were included in this analysis. Of women with adenomyosis, 83.8% in the relugolix combination therapy group were treatment responders compared with 27.6% in the placebo group. Amenorrhea was achieved in 64.9% of women with adenomyosis treated with relugolix combination therapy and in 6.9% of women treated with placebo. The least square mean uterine volume of women with adenomyosis decreased by 22.2% and 5.8% in the relugolix combination therapy and placebo groups, respectively. Results for the above outcomes in the relugolix combination therapy population were similar to the delayed relugolix combination therapy group.

CONCLUSION:

Efficacy outcomes in women with adenomyosis and UFs were comparable with those in women from the overall LIBERTY study population.

CLINICAL TRIAL IDENTIFICATION NUMBER:

LIBERTY 1, 2016-003727-27 (EudraCT) and NCT03049735; LIBERTY 2, 2016-005113-50 (EudraCT) and NCT03103087.

2025-01-01·Drug and therapeutics bulletin

▼Ryeqo for treatment of uterine fibroids

Article

2024-09-11·Cureus Journal of Medical Science

Abnormal Uterine Bleeding With Leiomyomas: A Case Report of Its Natural Course and Therapeutic Management

Article

作者: Gullabzada, Uzma ; Ahmed, Saba ; Ahmed, Samreen ; Jobanputra, Ketan ; Gullabzada, Mansoor

Uterine fibroids (UFs), or leiomyomas, are common benign tumors affecting a significant proportion of women by the age of 50 years. While typically non-cancerous, UFs can severely impact the quality of life (QoL) through symptoms such as heavy menstrual bleeding (HMB) and pelvic pain. We report a case of a 45-year-old Hispanic female with a history of hypertension, diabetes, nephrolithiasis, and a solitary kidney, who presented with symptomatic UFs and an ovarian cyst. Despite initial pharmacological treatment with Ortho Micronor and Myfembree, the patient experienced persistent symptoms, prompting surgical intervention. A supracervical hysterectomy, bilateral salpingectomy, lysis of adhesions, and left ovarian cystectomy were performed, resulting in symptom relief and benign postoperative findings. This case report highlights the need for personalized treatment plans and comprehensive patient counseling to manage complex gynecological conditions effectively.

项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的新闻（医药）

2025-08-01

·医药代表

住友制药宣布，完成中国区业务剥离

继续和小伙伴们分享跨国药企动态。7 月 31 日，住友制药日本总部宣布，包括中国区在内的亚洲业务，已于当日完成向丸红集团的股权转让手续。住友制药表示，上述公司分割及股份转让已于 2025 年 7 月 31 日完成，住友制药（中国）有限公司及住友制药亚太公司（Sumitomo Pharma Asia Pacific Pte. Ltd., SMPAP）不再是住友制药的合并子公司。至此，原负责亚洲业务的中国子公司“住友制药（中国）有限公司”，以及统管除日本与中国以外亚洲国家和地区业务的住友制药亚太公司，自该日起将不再作为合并子公司纳入财务报表。住友制药计划将在 2025 财年第二季度将此次转让所得约 450 亿日元计入其他收益（核心利润内）。早在今年 4 月 1 日，住友制药就已宣布与丸红株式会社的全资子公司——丸红环球制药公司（Marubeni Global Pharma）签订了股权转让协议等相关文件，现在正是基于该协议完成了实际的股权交割手续（见 MRCLUB 历史消息：一外企宣布，转让中国区药品业务！高管继续减薪…）。为推进此次亚洲业务的转让，住友制药先将“住友制药（中国）有限公司”、SMPAP 及其子公司所运营的亚洲业务，以吸收分割方式转移至其新设的全资子公司。随后，住友制药将该新公司已发行股份的 60% 转让给丸红全球制药公司。本次正是根据该方案，此次完成了 60% 股权的转让，住友制药预计将因此获得约 450 亿日元的对价收入。此外，住友制药所持有的新公司剩余 40% 股份也计划于 2029 年 4 月之后转让给丸红环球制药公司，届时预计将再获得约 270 亿日元的对价。住友制药表示，将利用此次出售亚洲业务所获取的资金，加速推进公司业务重组战略的核心——北美三大主力产品（Orgovyx、Myfembree、Gemtesa）的快速成长，同时也将用于推进两款抗肿瘤新药（TP-3654、DSP-5336）的研发，以实现尽早恢复业绩并重启公司增长轨道。今日（8 月 1 日），住友制药中国公司也宣布了这个消息，根据同年 4 月 1 日公布的《有关亚洲业务公司分立（简易吸收式分立）以及签署同丸红 Global Pharma 株式会社的股份转让协议和股东间协议的通知》所述，相关资产与股权的剥离及首期股权转让已顺利完成。住友制药中国表示，“我司（原住友制药中国）已从住友制药株式会社中独立，正式成为丸红集团的一员，开启全新的征程。”相关阅读：四十年，一家跨国药企的中国故事医药人变身公益侠，全球公益接力正式版来了！2025国谈时间确定2024年全球药品销售20强百万人从社会“消失”，药企VR破局官宣了，国药股份董事长确定康方生物代表被查，官方结果公布一药企总裁被罚1500万，10年禁入美威胁200%医药关税，引多国警惕第十一批国采报量启动，55个品种阿斯利康开线下年会了，近4000人上市药企90后少帅，突然辞去所有职务三度亮相链博会，诺和诺德以“链”会友家族药企，创始人辞职，管理层更换9900万元创新药“破题”基金！申报开启骨科主任受贿两百万，分给他人一半多22年老将即将谢幕，诺华CFO完成交棒罗氏、默克人事变动，中国医药总经理辞职药企财务造假！多位高管将被重罚最新10个重点监控药品公布17家药企上榜25年《财富》中国500强百年跨国药企诚聘英才！BI招聘专场国家市监总局公告，一药企被罚近四千万第三家药企罚单落地，副总经理闪电辞职肺癌新突破！复宏汉霖WCLC“秀肌肉”中央巡视组进驻！李健被查又一跨国医药巨头CFO退休百济神州寻找发光的你（附全国职位）AZ前高管加盟，百时美施贵宝迎来新任CMO一医学专家被查，曾任三甲医院院长阿斯利康中国，架构调整拜耳新一轮招聘启动，这次机会不要错过中央巡视组进驻，前省卫健委主任主动投案18家药企上榜2025年《财富》世界500强诺和诺德新任总裁兼首席执行官确定国家药监局原副局长陈时飞被开除党籍医疗反腐，这两天多人被查MRCLUB原创作者招募中数十万精准会员每日阅读，助您快速提升个人品牌，扩大在医药行业及社会化媒体的影响力！（详情请访问网站http://wemr.club）医药代表伴您成长！

财报并购引进/卖出

2025-07-07

·氨基观察

痛经药物的春天还要再等等

氨基观察-创新药组原创出品作者 | 沙晓薇在全球，大概每10个育龄女性中就有1个饱受子宫内膜异位症的折磨——这是一种影响约1.9亿女性的高发疾病，90%的患者经历着间断性的盆腔疼痛，26%甚至面临不孕的阴影。然而，当Organon近日宣布其“明星候选药物”OG-6219在二期临床试验中宣告失败时，这个本应充满希望的领域再次被蒙上阴霾。OG-6219曾被寄予厚望，被Organon视为“重塑痛经治疗标准”的突破，但它的失败不仅让Organon的女性健康创新管线陷入危机，更揭示了子宫内膜异位症药物研发的深层困境：一个影响数亿人的市场，为何新药寥寥无几？痛经药物的春天究竟何时才能到来？/ 01 /需求巨大，供给稀缺痛经，尤其严重的痛经，很可能是一种病——子宫内膜异位症。子宫内膜异位症远不止痛经那么简单，不仅可以侵袭周围组织和其他器官，导致复杂的症状，还容易在治疗后反复发作，直到绝经后才能缓解，给患者带来无尽的痛苦折磨。理论上，子宫内膜异位症拥有巨大的治疗需求与商业空间，但现实却是新药稀缺，研发缓慢。究其原因，还是对该疾病的基础研究仍处在模糊的“边缘地带”。研究认为原发性痛经与前列腺素合成过度有关，但其发病涉及激素异常、免疫炎症、神经敏化等多重因素的影响，真正的致病机制尚未厘清。这直接导致了新药研发的步履维艰。患者个体差异大，激素、子宫结构、炎症状态等因素复杂交错，进一步增加了研究的复杂性。由于缺乏有效的动物模型和生物标志物，疾病的分型及治疗选择无法达到共识，这也使新机制药物的转化率长期维持在低水平。更糟糕的是，许多女性将痛经视为“正常生理现象”，不了解子宫内膜异位症的存在，错过了早期干预时机，进一步增加了治疗难度。当然，非甾体抗炎药（NSAIDs）如布洛芬和双氯芬酸，仍是首选用药，但却“治标不治本”，能缓解疼痛，却无法根除病灶。而布洛芬的低价和高可及性（一瓶仅需几美元），无形中抬高了新药的准入门槛：如果新药无法显著超越NSAIDs的短期疗效，就很难在审评或商业化中胜出。艾伯维的Orilissa和辉瑞的Myfembree就是活生生的例子，这两款针对GnRHR的拮抗剂虽早已获批，但1000美元/月的高价、骨密度降低的副作用以及肝毒性问题，让市场接受度大打折扣。而ObsEva开发的口服GnRH拮抗剂linzagolix也曾试图上市，后因审评问题撤回申请，公司最终于2024年初停止运营。更早前，拜耳也曾布局这一领域，其靶向孕激素/催乳素（ER/PR）药物Visanne于2010年首次在欧洲获批，用于治疗子宫内膜异位症引发的疼痛，尽管与GnRH激动剂相比有更优的耐受性，但整体销售未能形成突破性增长。随着市场增长迟缓，收益不佳，拜耳原计划开展的与GnRH拮抗剂Elagolix的联合疗法项目也早早中止。这些案例背后，是药企的理性计算：机制不明、治疗意识不足，加上NSAIDs的强势市场地位，让大公司如拜耳也不得不“知难而退”。子宫内膜异位症正陷入需求巨大、供给稀缺的悖论负循环之中。/ 02 /失意者Organon如今，失意者的名单要再增添一位，2021年被默沙东拆分出来的Organon。为了摆脱“老药依赖”的标签，其通过并购打造自己的创新管线。2021年，Organon收购Forendo Pharma，代价是7500万美元的预付款，并承担900万美元的债务，以及最高9亿美元的里程碑付款。通过此次收购，Organon获得了后者的主打候选药物O6-6219。OG-6219被Organon寄予厚望，Organon的研发主管兼首席医疗官将其誉为“我们最大的潜在机遇”的口服药物。这是一种口服17β-羟类固醇脱氢酶1型（HSD17B1）抑制剂，其作用原理是阻断雌二醇激素的合成与转化过程。由于子宫内膜异位症及其导致的痛经、慢性盆腔痛往往由雌激素驱动，该机制有望从源头缓解病灶炎症与疼痛反应。与现有治疗手段（如GnRHR拮抗剂）通过系统性抑制激素不同，OG-6219具有组织选择性，能在不显著影响全身激素水平的前提下，“精准”地降低子宫内膜异位症病灶中的雌激素活性。这种更温和且可持续的药物治疗，能够避免部分激素失活引起的副作用，比如骨质疏松、血脂异常等。显然，Organon希望靠这一新机制药物，来解锁巨大的子宫内膜异位症市场。I期和Ib期试验数据也令人鼓舞，在绝经后和绝经前女性中均显示安全性和耐受性良好，全身激素水平未受影响。可惜的是，新药研发向来九死一生，早期数据良好、后期翻车的案例比比皆是，OG-6219也没能逃过这一劫。7月2日，Organon公告OG-6219 II期试验未达主要终点，OG-6219在减轻子宫内膜异位症相关的总体盆腔疼痛方面，并未表现出优于安慰剂的疗效。Organon决定停止OG-6219的临床开发。这对于Organon的创新管线布局，无疑是一大打击。从2024年财报看，其女性健康管线本就薄弱，仅有OG-6219、OG-7191（针对多囊卵巢综合征）和OG-9489（非激素避孕）三个项目，后两者尚处临床前阶段。OG-6219的失败对Organon来说不仅是一个研发项目的损失，还是管线信心和市场预期的坍塌。从公司此次公告来看，目前暂无其他研发管线能够接棒OG-6219。尽管Organon表示会继续子宫内膜异位症女性患者探索新的治疗方案，但是，鉴于该领域研发难度高、临床转化周期长，短期内重塑有竞争力的产品线难度较大。Organon在子宫内膜异位症这一适应症上的探索也可能面临被动调整。这无疑让本就创新乏乏的子宫内膜异位症的前景，再度被阴霾笼罩。/ 03 /春天还要再等等当然，OG-6219的失败固然令人扼腕，但子宫内膜异位症的药物创新并未终结。随着女性健康在全球范围内受到越来越多关注，一些企业仍在坚持投入。目前，在研项目仍然以PR、GnRH通路为主，但也出现了少量尝试突破传统的探索方向。例如，以色列的Gynica聚焦内源性大麻素通路，开发靶向CB1/CB2受体的疗法；英国的Ananda Pharma探索CBD类化合物控制神经性疼痛；美国的FimmCyte则从炎症反应切入，试图绕过激素路径。国内方面，虽然尚未有新靶点突破，但相关研究仍在不断推进。目前已有动物模型中尝试通过阻断CGRP或TAM/CSF1R/NTRK治疗子宫内膜异位症，此外，已有中药如散结镇痛胶囊获批用于临床治疗。只不过，整体上这些探索仍停留在临床前或概念验证阶段，短时间还难以改写现有的治疗格局。市场格局的改写，或许还要等待一场真正的技术革命——或许是基因编辑、AI驱动的药物发现，或是多组学技术对疾病机制的彻底解密。更关键的是产业决心的考验，药企需平衡短期回报与长期投入，而投资者往往对高风险领域望而却步。Organon的失败提醒我们，痛经药物的春天不会自动降临，这需要科学家的执着、企业的勇气，以及社会对女性健康的重新认知：痛经不是“忍忍就过去”的小事，而是数亿女性亟待解决的医疗需求。或许，当更多资源涌入、更多跨界合作诞生时，我们终将迎来破冰之日。但在此之前，春天还要再等等。有时候，等待本身，就是一场耐心的革命。PS：欢迎扫描下方二维码，添加氨基君微信号交流。

临床2期

2025-05-02

·PMLiVE

NHS patients to access Theramex’s endometriosis pill following NICE recommendation

NHS patients will soon be able to access Theramex’s once-a-day endometriosis pill Yselty (linzagolix), following final draft guidance from the National Institute for Health and Care Excellence (NICE). The health technology assessment agency has recommended the at-home treatment be used to manage endometriosis symptoms in patients across England, Wales and Northern Ireland with a history of previous medical or surgical treatment for their endometriosis. It will be given with add-back hormone therapy, which involves using low-dose hormone replacement therapy to minimise or eliminate menopause-like symptoms and bone loss. Affecting approximately 1.5 million women in the UK, endometriosis occurs when tissue similar to the lining of the uterus grows elsewhere in the body. Patients can experience a range of symptoms, including dysmenorrhoea (painful cramping, usually in the lower abdomen), heavy bleeding and pelvic pain. Yselty is designed to block the hormones that contribute to endometriosis symptoms. The drug is expected to be available in the coming months and could benefit more than 1,000 patients every year, according to NHS England. NICE’s decision was supported by results from the EDELWEISS 3 study, in which Yselty used alongside add-back therapy demonstrated statistically significant reductions in both co-primary endpoints of non-menstrual pelvic pain and dysmenorrhea compared to placebo. Sue Mann, national clinical director in women’s health for NHS England, said: “This is welcome news for women with endometriosis who haven’t found relief from previous therapies or surgery – it’s another treatment option which will help women take control of their health and better manage the symptoms of this often painful and debilitating condition.” NICE’s final guidance on Yselty is set to be published on 25 June, after which the NHS must make the treatment available within 90 days. The announcement comes less than two months after NICE recommended Gideon Richter’s Ryeqo (relugolix, estradiol and norethisterone) as the first long-term daily pill for endometriosis. Commenting on the agency’s latest decision, Emma Cox, chief executive at Endometriosis UK said: “Historic lack of research into women’s health means those with endometriosis have far too few options for managing their sometimes debilitating pain and other symptoms of endometriosis. “It’s good to see companies investing in research, and NICE approving a new drug for endometriosis, offering more choice for those considering medical menopause to manage symptoms.”

临床结果临床3期上市批准

100 项与瑞卢戈利/雌二醇/醋酸炔诺酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	H01CC	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	加拿大	Myovant Sciences GmbH	2023-10-17
出血	加拿大	Myovant Sciences GmbH	2023-09-22
子宫内膜异位症	美国	Sumitomo Pharma America, Inc.	2022-08-05
月经过多	美国	Sumitomo Pharma America, Inc.	2021-05-26
子宫肌瘤	美国	Sumitomo Pharma America, Inc.	2021-05-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
避孕	临床3期	美国	Sumitomo Pharma Co., Ltd.	2021-03-18
避孕	临床3期	波多黎各	Sumitomo Pharma Co., Ltd.	2021-03-18
痛经	临床3期	美国	Myovant Sciences GmbH	2017-11-01
痛经	临床3期	澳大利亚	Myovant Sciences GmbH	2017-11-01
痛经	临床3期	巴西	Myovant Sciences GmbH	2017-11-01
痛经	临床3期	智利	Myovant Sciences GmbH	2017-11-01
痛经	临床3期	捷克	Myovant Sciences GmbH	2017-11-01
痛经	临床3期	格鲁吉亚	Myovant Sciences GmbH	2017-11-01
痛经	临床3期	意大利	Myovant Sciences GmbH	2017-11-01
痛经	临床3期	新西兰	Myovant Sciences GmbH	2017-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03103087 \| NCT03049735 (LIBERTY 1, Pubmed \| Fertil Steril)	临床3期	子宫腺肌病 \| 子宫肌瘤	111	Relugolix combination therapy	構齋齋積鹽廠鏇艱積膚(糧製醖夢襯鬱鑰糧觸壓) = 遞繭淵衊窪醖淵餘繭窪築蓋製齋鹹糧壓構遞淵 (淵鹹衊鏇窪憲願鏇構積 ) 更多	积极	2025-09-01
				Placebo	構齋齋積鹽廠鏇艱積膚(糧製醖夢襯鬱鑰糧觸壓) = 觸醖鹹壓願窪簾獵顧憲築蓋製齋鹹糧壓構遞淵 (淵鹹衊鏇窪憲願鏇構積 ) 更多
NCT03103087 (CTgov)	临床3期	月经过多 \| 子宫肌瘤	382	Relugolix+Estradiol/norethindrone acetate (Relugolix Plus E2/NETA (Group A))	觸糧範窪獵簾齋繭壓鑰 = 襯選衊鏇選鹽築糧製膚壓鹽觸糧壓壓鹹醖獵淵 (糧餘網鹽觸淵網鏇餘顧, 鏇廠築蓋鏇憲壓製鑰觸 ~ 餘夢觸餘築蓋糧顧夢範) 更多	-	2022-04-20
				Estradiol/norethindrone acetate placebo (Placebo (Group C))	觸糧範窪獵簾齋繭壓鑰 = 鹽選醖淵襯鑰積憲襯膚壓鹽觸糧壓壓鹹醖獵淵 (糧餘網鹽觸淵網鏇餘顧, 繭選蓋醖鬱艱夢選鏇繭 ~ 鏇餘網觸顧選繭願顧襯) 更多
NCT03049735 (LIBERTY 1, CTgov)	临床3期	月经过多 \| 子宫肌瘤	388	Relugolix+Estradiol/norethindrone acetate (Relugolix Plus E2/NETA (Group A))	繭憲構築鏇製鹹網鹽範 = 範襯遞壓齋網襯築膚範簾淵選繭壓夢網鏇壓餘 (餘襯鬱選膚窪觸鏇願壓, 膚壓艱積築齋壓鹹鑰範 ~ 遞夢壓願選積獵襯構襯) 更多	-	2022-04-19
				Estradiol/norethindrone acetate placebo (Placebo (Group C))	繭憲構築鏇製鹹網鹽範 = 網獵廠遞積觸觸夢鑰鬱簾淵選繭壓夢網鏇壓餘 (餘襯鬱選膚窪觸鏇願壓, 顧願願艱糧憲衊範製廠 ~ 觸觸鑰網網鏇糧鬱餘築) 更多